EOC: 1 in 7 women develop VTE within 6 months of debulking surgery

  • Wagner BE & al.
  • Gynecol Oncol
  • 21 Nov 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Nearly 14% of women with epithelial ovarian cancer undergoing primary debulking surgery (PDS) develop venous thromboembolism (VTE) within 6 months.

Why this matters

  • Guidelines do not recommend VTE prophylaxis during outpatient, ambulatory chemotherapy in patients with solid tumors.

Study design

  • 888 women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer underwent PDS.
  • Primary outcome: VTE within 6 months.
  • Funding: None disclosed.

Key results

  • 3.2% of patients had VTE within 30 days of surgery.
  • Among 860 women without an immediate history of a VTE, the cumulative incidence of VTE at 30 days and 6 months was 7.5% and 13.8%, respectively.
  • Independent risk factors for diagnosis of VTE within 6 months:
    • macroscopic vs microscopic residual disease (aHR, 1.99; 95% CI, 1.35-2.94),
    • increasing estimated blood loss per doubling (aHR, 1.25; 95% CI, 1.05-1.49),
    • longer hospital length of stay (aHR, 3.00; 95% CI, 1.57-5.75), and
    • cardiac event within 30 days (aHR, 2.75; 95% CI, 1.56-4.80).
  • There were no differences in the risk for VTE within the first 30 days and 6 months between different VTE prophylaxes.

Limitations

  • Patients with recurrent disease and those who received neoadjuvant chemotherapy were not included.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit